Izmirly PM, et al. Longitudinal patterns and predictors of response to standard-of-care therapy in lupus nephritis: Data from the Accelerating Medicines Partnership Lupus Network. Arthritis Res Ther 2024; 26:54. doi: 10.1186/s13075-024-03275-z
GlaxoSmithKline (GSK). FDA approves GSK's Benlysta as the first medicine for adult patients with active lupus nephritis in the United States. December 17, 2020. Accessed March 14, 2024. https://www.gsk.com/en-gb/media/press-releases/fda-approves-gsk-s-benlysta-as-the-first-medicine-for-adult-patients-with-active-lupus-nephritis-in-the-us/
Aurinia. FDA approves Aurinia Pharmaceuticals’ Lupkynis™ (voclosporin) for adult patients with active lupus nephritis. January 22, 2021. Accessed March 14, 2024. https://www.auriniapharma.com/investors-and-media/news-events/press-releases/detail/210/fda-approves-aurinia-pharmaceuticals-lupkynis
Kidney Disease: Improving Global Outcomes (KDIGO). Lupis nephritis (LN). January 3, 2024. Accessed March 14, 2024. https://kdigo.org/guidelines/lupus-nephritis/
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021; 100:S1–S276. doi: 10.1016/j.kint.2021.05.021
GlaxoSmithKline (GSK). GSK for you. GSK pricing information: Benlysta. Accessed March 14, 2024. https://www.gskforyou.com/gsk-pricing-information/
Drugs.com. Lupkynis prices, coupons and patient assistance programs. Accessed March 14, 2024. https://www.drugs.com/price-guide/lupkynis
Institute for Clinical and Economic Review (ICER). Lupus nephritis: An assessment of voclosporin and belimumab. March 2021. Accessed March 14, 2024. https://icer.org/assessment/lupus-nephritis-2021/
Carlucci PM, et al. High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines Partnership. Rheumatology (Oxford) 2022; 61:4335–4343. doi: 10.1093/rheumatology/keac067
Fava A, et al. Urine proteomic signatures of histological class, activity, chronicity, and treatment response in lupus nephritis. JCI Insight 2024; 9:e172569. doi: 10.1172/jci.insight.172569
Fava A, et al. Urine proteomics and renal single-cell transcriptomics implicate interleukin-16 in lupus nephritis. Arthritis Rheumatol 2022; 74:829–839. doi: 10.1002/art.42023
Fava A, et al. Integrated urine proteomics and renal single-cell genomics identify an IFN-γ response gradient in lupus nephritis. JCI Insight 2020; 5:e138345. doi: 10.1172/jci.insight.138345